Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX‐68

Overview of attention for article published in Arthritis and rheumatism, January 2003

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

patent: 7 patents

guideline: 1 clinical guideline source

Readers on

mendeley: 72 Mendeley

So far, Altmetric has seen 7 patents that reference this research output.

A3 adenosine receptor allosteric modulators

Grant US-9326978-B2

United States of America

03 May 2016

Biological marker for inflammation

Grant US-8541182-B2

United States of America

24 Sep 2013

A3 adenosine receptor allosteric modulators

Grant US-8420664-B2

United States of America

16 Apr 2013

Genetic markers for prognosis of antifolate treatment efficacy

Grant US-8029998-B2

United States of America

04 Oct 2011

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 3 additional patents.